Investigation of an Updated Bone-anchored Sound Processor

Not Applicable

Completed

• Conditions: Hearing Loss; Hearing Loss, Conductive; Hearing Disorders; Otorhinolaryngologic Diseases; Sensation Disorders; Ear Diseases; Neurologic Manifestations; Deafness; Hearing Loss, Mixed; Nervous System Diseases
• Interventions: Device: Device A; Device: Device B

• Registration Number: NCT05086809
• Lead Sponsor: Oticon Medical

Brief Summary

The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor.

The performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.

Detailed Description

The investigation is a premarket investigation with the purpose of gathering knowledge on the performance of an updated sound processor compared to the CE marked Ponto 3 SuperPower sound processor to establish marketing claim(s) on the updated sound processor.

The recruitment for this clinical investigation will be performed among subjects who have already received a Ponto 3 SuperPower sound processor as a minimum three month prior to the study. 12-15 adult Ponto 3 SuperPower users with a conductive, mixed hearing loss or single-sided deafness will be included.

The study is a prospective, single-center, comparative, cross-over study with within-subject control design. The study includes four laboratory visits and three field trial periods. After the first trial period, which is included to ensure a homogenous baseline, the study is designed as a two-period, two-sequence crossover trial to compare the two sound processors (Device A \& Device B). Each participant is randomized into one of two sequences: (1) Device A then B, or (2) Device B then A, such that (about) half of the participants are assigned to one sequence and the other half to the second sequence.

This study is designed to combine audiological assessments (hearing and speech tests) in the laboratory and subjective self-reported outcomes collected during and after field trial periods with the investigational device and the comparator device (Ponto 3 SuperPower). The primary outcome of this study is to demonstrate that Open Sound Navigator in the updated sound processor provides subjects with improved speech recognition in noise.

Study Timeline

• Study First Submitted: 2021-09-27
• Study Start: 2021-09-30
• Status Verified: 2021-10
• Study First Submitted QC: 2021-10-07
• Study First Posted: 2021-10-21
• Primary Completion: 2021-12-13
• Study Completion: 2021-12-13
• Last Update Submitted: 2022-04-19
• Last Update Posted: 2022-04-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Signed Informed Consent Form

2. Adult subjects (18 years or older)

3. Subjects using a Ponto 3 SuperPower on Oticon Medical compatible abutment

4. Experienced BAHS users with a minimum experience of 3 months.

5. Subjects with:

   1. conductive or mixed hearing loss with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 65 dB HL as measured in situ with Ponto 3 SuperPower at Visit 1.
   2. OR subjects who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) as reported in the patient's Noah file.
   3. OR subjects who are indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS (as per investigator discretion).

6. Fluent in Danish

Exclusion Criteria

Subjects meeting any of the following criteria will not be permitted to participate in the investigation:

1. Known abnormally progressive BC hearing loss as judged by the investigator
2. Subjects with known mixed losses where the sensorineural part of the hearing loss is of retro-cochlear or central origin
3. Participation in another clinical investigation which might cause interference with study participation.
4. Subjects who do not have the ability or are un-willing to follow investigational procedures/requirements, e.g. to complete questionnaires, according to investigator's discretion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
ABA	Device B	Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.
AAB	Device B	Starts with Device A in first and second trial period and change to Device B in third trial period.
AAB	Device A	Starts with Device A in first and second trial period and change to Device B in third trial period.
ABA	Device A	Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.

Primary Outcome Measures

Name	Time	Method
To demonstrate that OSN in Device A provides subjects with improved speech recognition in noise.	4 weeks or 6 weeks	Difference in signal-to-noise ratio at 70% correct (referred to as SRT70) between OSN OFF and OSN ON after field trial with Device A (incl. automatics).

Secondary Outcome Measures

Name	Time	Method
To assess the degree to which Device A compensates for the BC hearing loss for the group CHL/MHL	Baseline	1. Effective gain defined as the difference in dB between aided sound field thresholds with Device A, and BC in-situ thresholds on the aided ear(s). The effective gain is calculated for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.; 2. Effective gain with Device A, see definition above, calculated in average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).
To assess the improvement in speech recognition in noise with Device B in full directional settings as compared to omnidirectional.	4 weeks or 6 weeks	Difference in signal-to-noise ratio at 70% correct (referred to as SRT70) between Omni and Full Dir after field trial with Device B.
To assess the improvement of hearing with Device A.	Baseline	1. Functional gain with Device A, i.e. the difference in dB between unaided and aided sound field thresholds, for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.; 2. Functional gain with Device A, see definition above, calculated on average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).
To assess the difference in BC thresholds as measured in-situ with Device A and via conventional BC audiometry.	Baseline and 2 weeks	Difference in dB between BC in situ thresholds and BC thresholds measured with conventional BC audiometry.
To assess the preference of BAHS sound processor.	6 weeks	Percentage (%) of subjects who prefer Device A over Device B in noisy sound environments.
To assess performance in speech recognition in noise with Device A and Device B in Omni settings.	Baseline	Difference in SRT70 between Device A and Device B in Omni settings as measured at Visit 1.
To assess self-reported ratings of sound quality, speech intelligibility, and overall performance with Device A and Device B.	1 week, 4 weeks and 6 weeks	1. Average ratings with Device A for each question of the "SPSK sound quality" questionnaire completed during the 1. field trial with Device A as obtained via phone interview; 2. Average ratings with Device A for each question of the "SPSK sound quality" questionnaire completed during the 2. or 3. field trial with Device A; 3. Average ratings with Device B for each question of the "SPSK sound quality" questionnaire completed during the 2. or 3. field trial with Device B; 4. Difference in ratings between Device A and Device B for each question of the "SPSK sound quality" questionnaire; 5. Average ratings with Device A for each question of the "SPSK situations" questionnaire completed during the 2. or 3. field trial with Device A; 6. Average ratings with Device B for each question of the "SPSK situations" questionnaire completed during the 2. or 3. field trial with Device B; 7. Difference in ratings between Device A and Device B for each question of the "SPSK situations" questionnaire
To assess the improvement in speech recognition with Device A in quiet.	2 weeks	Difference in speech recognition score in percent between unaided and aided, assessed in quiet on the aided ear(s).
To compare the improvement in speech recognition in noise with OSN ON in Device A (re Omni) with the improvement of full directionality in Device B (re Omni).	4 weeks or 6 weeks	Comparison of the difference in SRT70 between OSN OFF vs. OSN ON in Device A and Omni vs. Full Dir in Device B.
To assess the difference in BC thresholds as measured in-situ with Device A and Device B.	Baseline	Difference in dB between BC in situ thresholds measured with Device A and Device B.
To assess self-reported performance with Device A and Device B.	4 weeks or 6 weeks	1. Average SSQ12 scores with Device A for each question, sub-scales and in total.; 2. Average SSQ12 scores with Device B for each question, sub-scales and in total.; 3. Difference in SSQ12 scores between Device A and Device B for each question, sub-scales and in total.
To confirm the safety profile of the Device A in terms of the occurrence of adverse events and serious adverse events.	1 week, 2 weeks, 4 weeks and 6 weeks	Tabulated adverse events and serious adverse event related to the Device A reported throughout the study.

Trial Locations

Locations (1)

Oticon Medical c/o Oticon A/S; 🇩🇰 Copenhagen, Smørum, Denmark